This job is closed
We regret to inform you that the job you were interested in has been closed. Although this specific position is no longer available, we encourage you to continue exploring other opportunities on our job board.
Within The University of Texas MD Anderson Cancer Center lies a powerful engine driving the future of new targeted, immune- and cell-based therapies: the Therapeutics Discovery Division. Therapeutics Discovery eliminates the bottlenecks that hamper traditional drug discovery, with a multidisciplinary team of dedicated researchers, doctors, drug developers and scientific experts working together to develop small-molecule drugs, biologics and cellular therapies. Our unique structure and collaborative approach allow the team to work with agility, bringing novel medicines from concept to clinic quickly and efficiently - all under the same roof. The Therapeutics Discovery Division is built around four platforms: The Institute for Applied Cancer Science (IACS), ORBIT (Oncology Research for Biologics and Immunotherapy Translation), TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology) and the Neurodegeneration Consortium. The TRACTION platform is an industrialized translational research unit that aligns world-class drug discovery and development with highly innovative science and clinical care research. Through an investment in patient-centric research, we have developed the infrastructure, platforms, and capabilities to enable transformative research, partnering with leading clinical research scientists and physicians for which MD Anderson is known. TRACTION's approach combines large scale data science, innovative cancer genetics, epigenomics, disruptive technologies, deep mechanistic biology, disease modeling, and pharmacology to accelerate the translation of novel discoveries. As part of our mission, TRACTION is focused on partnering with our internal drug discovery engine (IACS, ORBIT, Biologics Development and Cell Therapies) and a growing list of external Partners (Boehringer Ingelheim, Taiho, Blueprint Medicines, Schrödinger and Obsidian) to discover and develop the next generation of small-molecule targeted therapies, antibody therapeutics and cell therapies, all driven by the needs we see in our patients. We work in a fast-paced, milestone-driven environment with a focus on team science and interdisciplinary research. Our unique approach has created a biotech-like engine within the walls of the nation's leading cancer center to bring life-saving medicines to our patients more quickly and effectively. This model already has achieved results, with multiple programs currently in clinical and late-stage preclinical development. We are currently seeking a highly motivated and talented Research Scientist to join our Reverse Translation group. With the deployment of advanced analytics, the group leverages unprecedented large-scale data science to provide insights and hypothesis that are rapidly functionally validated. We combine disruptive technologies, epigenomics and disease modelling to guide highly innovative science that leads to novel therapeutics, drug repurposing, novel combination or biomarker strategies that are quickly evaluated in the clinic. With this systematic and rapid reverse translation engine, we accelerate the discovery of transformative therapies and fuel prospective clinical trials to change standard-of-care (SOC) for unmet medical needs.
A Smarter and Faster Way to Build Your Resume